Medtronic, Inc. Nerve-Burning Device Failure "Colossal" Loss For Industry

The failure of Medtronic Inc. (MDT:US)’s nerve-burning device to treat high blood pressure in a clinical trial deals a blow to more than 60 companies pursuing similar technology. Medtronic, the world’s biggest maker of heart rhythm devices, said today it will suspend patient enrollment in the U.S., Japan, and India, where studies were being conducted for regulatory approval. The procedure, called renal denervation, works by searing nerves in arteries near the kidney to quell the production of hormones involved in blood-vessel contraction.

Hey, check out all the engineering jobs. Post your resume today!